Evidence map›Paper›PMID 23955597›Full record

ArticleNature genetics2013

Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk.

Daniel Chubb, Niels Weinhold, Peter Broderick, Bowang Chen, David C Johnson, Asta Försti, Jayaram Vijayakrishnan, Gabriele Migliorini, Sara E Dobbins, Amy Holroyd and 25 more

Registry-linked trialOpen access · greenAbstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature genetics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05539079 (A Prospective Long-term Observational Study in Patients With Monoclonal Gammopathy of Undetermined Significance), which is not on this map. Cited by 100 papers, 19 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 19 pooled it
11.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05539079 recruitingnot on this mapstarted 2023, after this paper: background citation

A Prospective Long-term Observational Study in Patients With Monoclonal Gammopathy of Undetermined Significance

TypeobservationalSponsorOxford University Hospitals NHS TrustRan2023 to 2032Enrolled2,000ConditionsMGUS
3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 19 syntheses or guidelines pooled it, 164 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2016
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Trial

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 14 institutions in 3 countries.

Daniel Chubb *Division of Genetics and Epidemiology, Institute of Cancer Research, Surrey, UK.
Niels Weinhold *Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Peter BroderickDivision of Genetics and Epidemiology, Institute of Cancer Research, Surrey, UK.
Bowang ChenGerman Cancer Research Center, Heidelberg, Germany.
David C JohnsonHaemato-Oncology, Division of Pathology, Institute of Cancer Research, Surrey, UK.
Asta FörstiGerman Cancer Research Center, Heidelberg, Germany.
Jayaram VijayakrishnanDivision of Genetics and Epidemiology, Institute of Cancer Research, Surrey, UK.
Gabriele MiglioriniDivision of Genetics and Epidemiology, Institute of Cancer Research, Surrey, UK.
Sara E DobbinsDivision of Genetics and Epidemiology, Institute of Cancer Research, Surrey, UK.
Amy HolroydDivision of Genetics and Epidemiology, Institute of Cancer Research, Surrey, UK.
Dirk HoseDepartment of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Brian A WalkerHaemato-Oncology, Division of Pathology, Institute of Cancer Research, Surrey, UK.
Faith E DaviesHaemato-Oncology, Division of Pathology, Institute of Cancer Research, Surrey, UK.
Walter A GregoryUniversity of Leeds, Leeds, UK.
Graham H JacksonRoyal Victoria Infirmary, Newcastle upon Tyne, UK.
Julie A IrvingNewcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle-upon-Tyne, UK.
Guy PrattDepartment of Haematology, Birmingham Heartlands Hospital, Birmingham, UK.
Chris FeganDepartment of Haematology, School of Medicine, Cardiff University, Cardiff, UK.
James Al FentonLeeds Teaching Hospitals NHS Trust, Leeds, UK.
Kai NebenDepartment of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Per HoffmannInstitute of Human Genetics, University of Bonn, Germany.
Markus M NöthenInstitute of Human Genetics, University of Bonn, Germany.
Thomas W MühleisenInstitute of Human Genetics, University of Bonn, Germany.
Lewin EiseleInstitute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, University Duisburg-Essen, Germany.
Fiona M RossCytogenetics Group, Wessex Regional Cytogenetic Laboratory, Salisbury, UK.
Christian StrakaSchön Klinik Starnberger See, Berg, Germany.
Hermann EinseleUniversity Clinic of Würzburg, Würzburg, Germany.
Christian LangerDepartment of Internal Medicine III, University of Ulm, Ulm, Germany.
Elisabeth DörnerDepartment of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
James M AllanNewcastle Cancer Centre, Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle-upon-Tyne, UK.
Anna JauchInstitute of Human Genetics, University of Heidelberg, Germany.
Gareth J MorganHaemato-Oncology, Division of Pathology, Institute of Cancer Research, Surrey, UK.
Kari HemminkiGerman Cancer Research Center, Heidelberg, Germany.
Richard S HoulstonDivision of Genetics and Epidemiology, Institute of Cancer Research, Surrey, UK.
Hartmut GoldschmidtDepartment of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Institute of Cancer Research · GBHeidelberg University · DEGerman Cancer Research Center · DEUniversity of Bonn · DENewcastle University · GBCardiff University · GBHeartlands Hospital · GBInstitut für Medizinische Informatik, Biometrie und Epidemiologie · DENational Health Service · GBRoyal Victoria Infirmary · GBUniversität Ulm · DEUniversity of Leeds · GBUniversity of Würzburg · DEWessex Regional Genetics Laboratory · GB

Funding

Cancer Research UK C1298/A8362Wellcome Trust
6 · The paper itself

Abstract

To identify variants for multiple myeloma risk, we conducted a genome-wide association study with validation in additional series totaling 4,692 individuals with multiple myeloma (cases) and 10,990 controls. We identified four risk loci at 3q26.2 (rs10936599, P = 8.70 × 10(-14)), 6p21.33 (rs2285803, PSORS1C2, P = 9.67 × 10(-11)), 17p11.2 (rs4273077, TNFRSF13B, P = 7.67 × 10(-9)) and 22q13.1 (rs877529, CBX7, P = 7.63 × 10(-16)). These data provide further evidence for genetic susceptibility to this B-cell hematological malignancy, as well as insight into the biological basis of predisposition.

Indexed as

Chromosome AberrationsChromosomes, HumanGenetic Predisposition to DiseaseCase-Control StudiesHumansMultiple Myeloma

Identifiers

PMID23955597
PMCPMC5053356
OpenAlexW2058827066

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.